Olivia J. Haller

Olivia J. Haller

Auto-generated profile, based on publicly available information

Olivia J. Haller

School of Biomedicine, The University of Adelaide, South Australia, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2023 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
ISInes Semendric
Ines Semendric
DPDanielle Pollock
Danielle Pollock
OHOlivia J. Haller
Olivia J. Haller
RGRebecca P. George
Rebecca P. George
LCLyndsey E Collins-Praino
Lyndsey E Collins-Praino
Alex WhittakerAlex Whittaker
Alex Whittaker
Purpose: To examine children’s experiences of chemotherapy-induced cognitive impairment––colloquially “chemobrain”––and the impact on children’s social, academic, and daily living skills via a qualitative systematic review. Experiencing chemotherapy as a child, when the brain is still developing, may cause lifelong detriment to survivors’ lives. There is a significant gap in understanding their lived experience, including the self-identified barriers that children face following treatment. Such a gap can only be fully bridged by listening to the child’s own voice and/or parent proxy report through an exploration of the qualitative research literature. Methods: A search of MEDLINE, Embase, PsycINFO, and CINAHL databases was conducted. Inclusion criteria were qualitative studies with a focus on children (0–18 years) during and/or following chemotherapy treatment and explored children’s experiences of chemobrain. Results: Two synthesized findings were identified from six studies. (1) Chemobrain has an academic and psychosocial impact, which may not be understood by education providers. (2) Children and their parents have concerns about their reintegration and adaptation to school, social lives, and their future selves as independent members of society. Children’s experiences primarily related to changes in their academic and social functioning. Conclusion: This review highlights two important considerations: (1) the lived experiences of pediatric childhood cancer survivors guiding where future interventions should be targeted, and (2) a need to perform more qualitative research studies in this area, as well as to improve the quality of reporting among the existing literature, given that this is a current gap in the field.

9 March 2023 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
OHOlivia J. Haller
Olivia J. Haller
ISInes Semendric
Ines Semendric
RGRebecca P. George
Rebecca P. George
LCLyndsey E. Collins-Praino
Lyndsey E. Collins-Praino
Alex WhittakerAlex Whittaker
Alex Whittaker
Chemotherapy-induced cognitive impairment (CICI) is a debilitating condition resulting from chemotherapy administration for cancer treatment. CICI is characterised by various cognitive impairments, including issues with learning, memory, and concentration, impacting quality of life. Several neural mechanisms are proposed to drive CICI, including inflammation, therefore, anti-inflammatory agents could ameliorate such impairments. Research is still in the preclinical stage; however, the efficacy of anti-inflammatories to reduce CICI in animal models is unknown. Therefore, a systematic review was conducted, with searches performed in PubMed, Scopus, Embase, PsycInfo and Cochrane Library. A total of 64 studies were included, and of the 50 agents identified, 41 (82%) reduced CICI. Interestingly, while non-traditional anti-inflammatory agents and natural compounds reduced impairment, the traditional agents were unsuccessful. Such results must be taken with caution due to the heterogeneity observed in terms of methods employed. Nevertheless, preliminary evidence suggests anti-inflammatory agents could be beneficial for treating CICI, although it may be critical to think beyond the use of traditional anti-inflammatories when considering which specific compounds to prioritise in development.

10 December 2024 in Behavioural Brain Research
Verified
Journal Article
Open access
OHOlivia J. Haller
Olivia J. Haller
ISInes Semendric
Ines Semendric
LCLyndsey E. Collins-Praino
Lyndsey E. Collins-Praino
AWAlexandra L. Whittaker
Alexandra L. Whittaker
RGRebecca P. George
Rebecca P. George
Chemotherapy-induced cognitive impairment (CICI) affects female cancer survivors, with impairment recognised in populations such as breast cancer survivors, where 1 in 3 are affected. Impairments include issues with memory, learning, concentration, and processing speed, negatively impacting quality of life. Several mechanisms are proposed to drive these, with evidence implicating neuroinflammation as a key contributor. However, the time course over which impairments occur is less well-established, with fewer longer-term time-points investigated. This study aimed to understand the evolution of cognitive changes following methotrexate (MTX) or 5- fluorouracil (5-FU) chemotherapy, assessing three time-points: acute (96-hour), sub-acute (31-days) and chronic (93-days). Further, we investigated whether alterations in cognition were associated with concomitant changes in astrocytic reactivity. Female Sprague Dawley rats received two intraperitoneal injections of MTX, 5-FU or saline and were assessed on the novel object recognition, 5-choice serial reaction time task and Barnes maze. Hippocampal and prefrontal cortex tissue was examined for GFAP expression. Both MTX and 5-FU exposure were associated with spatial memory, task acquisition, and processing speed impairments at 31-days, with impairment ameliorated by 93-days. While both MTX and 5-FU induced changes in GFAP expression across various time-points and regions, with most notable changes at 96-hours, 5-FU exhibited expression changes in the hippocampus consistently across all time-points. These results provide valuable insight into the complexity of a mediator of neuroinflammation in CICI. While neuroinflammation may be a promising therapeutic target, further markers should be assessed to elucidate the full neuroimmune response, and thus which aspects to target and when, to ensure optimal outcomes for cancer patients treated with chemotherapy.

21 October 2026 in Behavioural Brain Research
Verified
Journal Article
Open access
OHOlivia J. Haller
Olivia J. Haller
LCLaura May Carr
Laura May Carr
ISInes Semendric
Ines Semendric
RGRebecca P. George
Rebecca P. George
Alex WhittakerAlex Whittaker
Alex Whittaker
LCLyndsey E Collins-Praino
Lyndsey E Collins-Praino

27 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
OHOlivia J. Haller
Olivia J. Haller
ISInes Semendric
Ines Semendric
LCLyndsey E Collins-Praino
Lyndsey E Collins-Praino
Alex WhittakerAlex Whittaker
Alex Whittaker
RGRebecca P. George
Rebecca P. George
Chemotherapy-induced cognitive impairment (CICI) affects up to 75% of cancer survivors between 6-months and 20-years post-treatment. Impairments include memory loss, learning difficulties, inability to concentrate and a decrease in processing speed, all of which can negatively impact quality of life. Several mechanisms are proposed to drive these impairments, with evidence implicating neuroinflammation as a key contributor. However, the time course over which impairments occur is less well-established. Several preclinical studies have focused on acute (0-7 days) and sub-acute (8-days to 12-weeks) time-points following chemotherapy, but few have investigated more longer-term time-points. This study therefore aimed to understand the evolution of cognitive changes following methotrexate (MTX) or 5-flurouracil (5-FU) chemotherapy treatment, assessing three time-points: acute (96-hour), sub-acute (31-days) and chronic (93-days). Further, we investigated whether alterations in cognition were associated with concomitant changes in neuroinflammation, assessed via astrocytic reactivity. Female Sprague Dawley rats received two intraperitoneal injections of MTX, 5-FU or saline and were assessed on the novel object recognition, 5-choice serial reaction time task and Barnes maze. Hippocampal (HIPP) and pre-frontal cortex (PFC) tissue was examined for GFAP expression. Results indicate that both MTX and 5-FU exposure were associated with impairments in spatial memory, task acquisition, and processing speed at 31-days, with impairment ameliorated by 93-days post-treatment. While MTX and 5-FU increased GFAP expression across all time-points, with the largest changes at 96-hours and 31-days, drug-specific and region-specific variations were noted. These results provide valuable insight into the complexity of the neuroinflammatory response in CICI. While neuroinflammation may be a promising therapeutic target, further work is required to fully understand this response, including which aspects to target and at what time-points, to ensure optimal outcomes for cancer patients treated with chemotherapy.